NovaBay Pharmaceuticals, Inc. (NBY) financial statements (2022 and earlier)

Company profile

Business Address 2000 POWELL STREET, SUITE 1150
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,50411,9526,9373,1833,1999,5122,385
Cash and cash equivalents7,50411,9526,9373,1833,1999,5122,385
Receivables1,6681,1061,0663,3853,6292,120536
Inventory, net of allowances, customer advances and progress billings3,2206084922805048731,345
Inventory3,2206084922805048731,345
Prepaid expense152165941301231,966261
Other current assets144102105279347  
Other undisclosed current assets4823096871,3511,193  
Total current assets:13,17014,2429,3818,6088,99514,4714,527
Noncurrent Assets
Operating lease, right-of-use asset4114361,252
Property, plant and equipment19384110201471371395
Intangible assets, net (including goodwill)9,728      
Goodwill4,528      
Intangible assets, net (excluding goodwill)5,200      
Other noncurrent assets476476477552613539155
Total noncurrent assets:10,8089961,8397531,084910550
TOTAL ASSETS:23,97815,23811,2209,36110,07915,3815,077
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,1372,4172,1093,8062,1382,2564,463
Accounts payable1,0453023315514664552,483
Accrued liabilities2,0922,1151,7783,2551,6721,8011,980
Deferred revenue  434
Debt105 2,339    
Derivative instruments and hedges, liabilities  3    
Deferred revenue and credits2,8412,067170
Contract with customer, liability2,398
Other undisclosed current liabilities200416802(2,357)   
Total current liabilities:3,4422,8335,6873,8474,9794,3234,633
Noncurrent Liabilities
Long-term debt and lease obligation24687505    
Operating lease, liability24687505
Liabilities, other than long-term debt561  3821,0172,5113,887
Deferred revenue and credits8022,3132,437
Deferred rent credit   184
Other liabilities   1982151981,450
Business combination, contingent consideration, liability561      
Other undisclosed noncurrent liabilities9,558(87)4,0551781,4891,4461,655
Total noncurrent liabilities:10,365874,5605602,5063,9575,542
Total liabilities:13,8072,92010,2474,4077,4858,28010,175
Stockholders' equity
Stockholders' equity attributable to parent, including:10,17112,3189734,9542,5947,101(5,098)
Preferred stock680      
Common stock47841827917115415335
Additional paid in capital150,900147,963125,718119,764113,514110,61985,387
Accumulated deficit(141,887)(136,063)(125,024)(114,981)(111,074)(103,671)(90,520)
Warrants and rights outstanding    1,489  
Other undisclosed stockholders' equity attributable to parent    (1,489)  
Total stockholders' equity:10,17112,3189734,9542,5947,101(5,098)
TOTAL LIABILITIES AND EQUITY:23,97815,23811,2209,36110,07915,3815,077

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues8,4219,9346,59912,50818,23011,8974,381
Revenue, net18,23011,8974,381
Cost of revenue
(Cost of Goods and Services Sold)
(2,776)(3,970)(1,738)(1,503)(2,784)(2,464)(1,261)
Gross profit:5,6455,9644,86111,00515,4469,4333,120
Operating expenses(14,507)(12,390) (18,876)(22,757)(20,415)(24,134)
Operating income (loss):(8,862)(6,426)4,861(7,871)(7,311)(10,982)(21,014)
Nonoperating income (expense)(1,577)605 1912(2,167)2,053
Investment income, nonoperating     (2,099)2,149
Other nonoperating income (expense)(1,577)605 1912(68)(96)
Interest and debt expense  (18)    
Income (loss) from continuing operations before equity method investments, income taxes:(10,439)(5,821)4,843(7,852)(7,299)(13,149)(18,961)
Other undisclosed income (loss) from continuing operations before income taxes4,615(5,213)(14,495)1,311(101)  
Loss from continuing operations before income taxes:(5,824)(11,034)(9,652)(6,541)(7,400)(13,149)(18,961)
Income tax expense (5) (4)(3)(2)(2)
Loss before gain (loss) on sale of properties:(5,824)(11,039)(9,652)(6,545)(7,403)(13,151)(18,963)
Other undisclosed net loss      (10)
Net loss:(5,824)(11,039)(9,652)(6,545)(7,403)(13,151)(18,973)
Other undisclosed net loss attributable to parent  (6)    
Net loss attributable to parent:(5,824)(11,039)(9,658)(6,545)(7,403)(13,151)(18,973)
Preferred stock dividends and other adjustments(735) (829)    
Net loss available to common stockholders, basic:(6,559)(11,039)(10,487)(6,545)(7,403)(13,151)(18,973)
Dilutive securities, effect on basic earnings per share   (1,311)   
Net loss available to common stockholders, diluted:(6,559)(11,039)(10,487)(7,856)(7,403)(13,151)(18,973)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(5,824)(11,039)(9,652)(6,545)(7,403)(13,151)(18,973)
Comprehensive loss, net of tax, attributable to parent:(5,824)(11,039)(9,652)(6,545)(7,403)(13,151)(18,973)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: